Medication Management in Pregnancy

Indications for Medication

• The American Academy of Child and Adolescent Psychiatry recommends prioritizing medication over psychotherapy in patients with a history of severe depression or suicide attempts, with previous positive response to antidepressants, previous relapse upon discontinuation of antidepressants, inadequate response to psychotherapy, or patient preference for medication, with a moderate strength of evidence 1
• The use of SSRIs during pregnancy is associated with impaired feto-placental function, increased risk of premature delivery, potential for miscarriage, low fetal growth, and significant maternal morbidity, highlighting the need for careful consideration of maternal mental health needs against potential fetal risks 1

Maternal Mental Health Considerations

• Recent research suggests that many adverse outcomes previously attributed to SSRI exposure may actually be related to underlying maternal depression, emphasizing the importance of balancing maternal mental health needs against potential fetal risks, with a moderate strength of evidence 1
• The American Academy of Child and Adolescent Psychiatry recommends monitoring, exercise, and social support for patients with mild depression, with a moderate strength of evidence 1
• The American College of Physicians recommends Cognitive Behavioral Therapy (CBT) as an initial treatment approach for most patients with anxiety disorders during pregnancy, with improved symptoms and decreased relapse rates, and no reported harms due to psychological therapies 2

Safety and Risks of Antidepressants

• The use of antidepressants during pregnancy, particularly sertraline, is relatively safe when clinically indicated, and the risks of untreated depression generally outweigh the potential risks of medication, according to the American Academy of Child and Adolescent Psychiatry, with a moderate strength of evidence 1
• Potential risks of SSRI exposure include neonatal adaptation syndrome, possible small increased risk of persistent pulmonary hypertension of the newborn (PPHN), and potential cardiac malformations, as reported by the American family physician 3
• The FDA categorizes SSRIs as category C, meaning they should be given only if potential benefits justify the potential risk to the fetus, according to the European Heart Journal 4

Preferred Antidepressant Options

• Sertraline is a preferred first-line option due to its established safety profile, and citalopram is generally considered safe, as indicated by the American family physician 3
• Paroxetine is FDA classified as pregnancy category D due to concerns about congenital cardiac malformations, as indicated by the American family physician 3

Monitoring and Management of Neonatal Symptoms

• Antidepressant use, specifically SSRI use, during pregnancy is associated with a constellation of neonatal symptoms, including crying, irritability, tremors, poor feeding, hypertonia, tachypnea, sleep disturbance, hypoglycemia, and seizures, as supported by the American Academy of Family Physicians and the American Academy of Pediatrics 3, 5
• SSRI exposure during the third trimester can lead to neonatal adaptation syndrome, characterized by continuous crying and irritability, jitteriness and restlessness, shivering and fever, tremors, hypertonia or rigidity, tachypnea or respiratory distress, feeding difficulties, sleep disturbance, hypoglycemia, and seizures, with a strength of evidence level of moderate to high 5
• For infants exposed to SSRIs during pregnancy, monitoring for signs of drug toxicity or withdrawal during the first week of life, arranging early follow-up after initial hospital discharge, and considering a short-term course of chlorpromazine for symptom relief in severely affected infants are recommended by the American Academy of Pediatrics 5

Breastfeeding Considerations

• Monitoring recommendations for breastfed infants include watching for irritability, poor feeding, or sleep disturbances, with particular caution for premature or low birth weight infants, as suggested by the American Academy of Pediatrics 5, 6

• The American Academy of Pediatrics recommends individualized treatment with SSRIs during pregnancy, balancing maternal risk of untreated illness versus potential fetal risk, and sertraline monotherapy is recommended as a first-line option for treating depression and anxiety during pregnancy, due to its established safety profile and lower risk of adverse outcomes, with a strength of evidence level of moderate to high 6, 5